Fidest – Agenzia giornalistica/press agency

Quotidiano di informazione – Anno 32 n° 220

Posts Tagged ‘medicines’

Nasce il Gruppo autonomo delle Value Added Medicines

Posted by fidest press agency su martedì, 28 gennaio 2020

Di “vecchio” hanno solo la data sull’atto di prima registrazione. Ma nel DNA hanno la capacità e la voglia di offrire nuove soluzioni a bisogni sanitari insoddisfatti o di migliorare significativamente la gestione di terapie consolidate nelle diverse aree terapeutiche di appartenenza. Sono le Value Added Medicines, di cui all’estero si discute ormai già da qualche anno: i medicinali a valore aggiunto che utilizzano principi attivi noti e di indiscussa efficacia introducendo delle “innovazioni” che ne migliorano le performance regalando loro una marcia in più rispetto a qualsiasi precedente versione.A dar voce alle aziende impegnate in questo settore sarà un Gruppo autonomo, appena battezzato nell’ambito di Assogenerici: l’Italian VAM Group, che ieri ha eletto come proprio coordinatore Geremia Seclì (Medac Pharma) e come vice coordinatore Raffaelle Marino (Zentiva Italia).Obiettivo del neonato Gruppo – che è aperto anche all’adesione di aziende non appartenenti ad Assogenerici – è quello di contribuire tramite i nuovi prodotti a migliorare l’aderenza alle terapie e i risultati sulla salute o sulla qualità della vita; incrementare la sicurezza ed efficienza del personale sanitario; allargare le opzioni di trattamento e prevenzione; migliorare il rapporto costi-benefici e infine accesso all’assistenza sanitaria.Al gruppo hanno già aderito 10 aziende già trasversalmente attive sia nel settore delle small molecules che in quello dei biologici (ABC Farmaceutici, Accord Healthcare, Baxter, Medac, Mylan, Italia, NTC, Sun Pharma, Salf, Teva, Zentiva Italia) e si sta registrando l’interesse di aziende attualmente non associate ad Assogenerici. «Le VAM includono una grande varietà di prodotti off patent modificati o combinati prevedendo ad esempio nuove forme farmaceutiche, vie di somministrazione, dosaggi, indicazioni, devices, soluzioni digitali e patient support programs», spiega, il neo-coordinatore Seclì.«Esiste un significativo potenziale non sfruttato in Europa per ottimizzare le terapie esistenti per soddisfare al meglio le esigenze di pazienti, operatori sanitari e pagatori – conclude Marino – una maggiore personalizzazione delle terapie esistenti non può che portare ad una maggiore efficienza per l’intera comunità sanitaria».

Posted in Medicina/Medicine/Health/Science | Contrassegnato da tag: , | Leave a Comment »

3rd Annual Genetic Medicines Conference

Posted by fidest press agency su lunedì, 7 ottobre 2019

The Medicines Company (NASDAQ:MDCO) announced that it will participate in the Chardan 3rd Annual Genetic Medicines Conference on Tuesday, October 8, 2019, in New York. The Company is scheduled to participate in a “fireside chat” discussion at 8:00 a.m. Eastern Daylight Time.A live audio webcast will be available on The Medicines Company Investor Relations website and a replay of the presentation will be available within 48 hours of the event.
The Medicines Company (NASDAQ: MDCO) is a biopharmaceutical company with a singular, relentless focus on addressing the greatest global healthcare challenge and burden today – cardiovascular disease. Our purpose is to halt the deadly progression of atherosclerosis and the cardiovascular risk created by high levels of LDL-C. The Company is headquartered in Parsippany, New Jersey.

Posted in Estero/world news | Contrassegnato da tag: , , , | Leave a Comment »

Translational Regenerative Medicines – Global Market Outlook

Posted by fidest press agency su domenica, 28 luglio 2019

According to this research, the Global Translational Regenerative Medicines Market is growing at a CAGR of 13.9% from 2017 to 2026.Factors such as the increasing prevalence of degenerative diseases, rise in aging population and growing advancements in developed countries are the major driving factors. However, ethical concerns related to the use of embryonic stem cells in research & development hinders market growth.By Product Type, the Gene therapy segment is expected to have significant growth during the forecast period. Gene therapy assists the foundation for innovative treatments of innumerable musculoskeletal disorders. By geography, North America dominated the global regenerative medicine market owing to an increased number of leading companies and growth in the expansion of research and development activities in the U.S.Some of the key players profiled in the Translational Regenerative Medicines Market include Vericel Corporation, Gamida Cell Ltd., Athersys, Inc., Orthofix International N.V, Anika Therapeutics, Novartis, Celgene Corporation, Brainstorm Cell Therapeutics Inc., Nuvasive, Inc., and Medipost.

Posted in Estero/world news | Contrassegnato da tag: , | Leave a Comment »

Ensuring Access to Medicines for Patients: Pharmaceutical industry associations

Posted by fidest press agency su mercoledì, 21 gennaio 2015

BruxellesBrussels, AESGP, EFPIA, EGA, and PPTA are pleased to announce today’s release of the joint principles for “Communication of information on quality and manufacturing potential supply disruption”. This document forms part of the industry response to the EMA (European Medicines Agency) call for voluntary and proactive action, to provide European patients with continuous access to medicines.
There can be multiple causes to medicines shortages, including issues relating to quality and manufacturing. In cases where a disruption to the manufacturing process of a medicine arises, Marketing Authorisation Holders (MAHs) are obligated to timeously notify Competent Authorities (CAs). This document addresses such communications, and complements the output from the professional organisations ISPE & PDA on the prevention of such supply disruptions – see enclosed summary report.
This ‘Principles’ document introduces a harmonised approach to the communication of information by MAHs, meeting the complex and divergent data requirements across national CAs and EMA. This is expected to facilitate coordinated action between CAs; it will further enable CAs to gather standardised data for the identification and analysis of the causes, while considering mitigation strategies. This ‘Principles’ document constitutes a first and concrete step in the right direction and was warmly welcomed by the EMA and national CAs.AESGP, EFPIA, EGA, and PPTA believe that more can be achieved within the EMA initiative, particularly on reporting and notification mechanisms beyond manufacturers, which should form the next key milestone of the EMA initiative for 2015. This necessitates an integrated solution involving all stakeholders in the supply chain, illustrated in the recent report commissioned by DG Sanco1.The pharmaceutical industry is fully committed to working with these stakeholders, to mitigate factors that could contribute to supply disruptions, and to provide European patients with continuous access to the medicines they need.

Posted in Economia/Economy/finance/business/technology, Estero/world news, Medicina/Medicine/Health/Science | Contrassegnato da tag: , , , | Leave a Comment »